ArriVent BioPharma, Inc. (AVBP)
ArriVent BioPharma develops cancer medicines, led by firmonertinib for certain types of lung cancer. It last closed at $10.69 on Nov 17, down 7.53% on the day. The average 12-month price target from 7 analysts is $25.57 (+139.2% from the last close), with a high of $29.00 and a low of $20.00. Analyst consensus is Strong Buy, based on the latest ratings from 7 firms (7 buy, 0 hold, 0 sell). In the past 30 days there were 1 dark pool print totaling $316K, the largest $316K.
Key Stats
Last 12 monthsNot reported for this period.
From AVBP's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 9). Last 12 months adds up the four latest quarters.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 7 analysts who set a price target on AVBP in the past 90 days. The average target is $25.57, with a high of $29.00 and a low of $20.00, compared with the last close of $10.69.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Nov 16 | Guggenheim | Target lowered | Buy | $30 → $28 |
| Nov 10 | Truist Securities | Target raised | Buy | $18 → $24 |
| Oct 27 | Guggenheim | Target raised | Buy | $18 → $30 |
| Oct 20 | B. Riley Securities | Maintained | Buy | $29 |
| Oct 8 | HC Wainwright & Co. | Target lowered | Buy | $47 → $27 |
Technical Analysis
The stock is 36% below its 20 day and 92% below its 50 day average. It is 147% below its 200 day average, so the longer trend is down. Momentum is weak (RSI 28), oversold. The nearest support is the 52 week low at $10.49, and the nearest resistance the Pivot at $11.02.
| RSI (14) | 27.96 | Oversold below 30 | Oversold |
| MACD | -2.37 | Above its signal line | Bullish |
| Stochastic | 8.8 | Near the bottom of its range | Oversold |
| ADX (14) | 33.4 | Trending down | |
| Williams %R | -96.7 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -127.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −17.9% | Change over 10 sessions | Bearish |
| ATR (14) | $1.46 | Typical daily range, 13.7% of price |
| RSI (14) | 25.74 | Oversold below 30 | Oversold |
| MACD | -3.99 | Below its signal line | Bearish |
| Stochastic | 6.7 | Near the bottom of its range | Oversold |
| ADX (14) | 27.1 | Trending down | |
| Williams %R | -99.1 | Oversold below −80, overbought above −20 | Oversold |
| CCI (20) | -136.5 | Oversold below −100, overbought above 100 | Oversold |
| Rate of change | −63.1% | Change over 10 sessions | Bearish |
| ATR (14) | $3.91 | Typical daily range, 36.6% of price |
What happened before
See how AVBP did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Whale Options Flow
90DNo whale options trades in AVBP in the last 90 days.
Dark Pool
30DAVBP Institutional Ownership
Full report →- ▲85 buying vs 61 selling
- ▲Held by funds +8.4 pts
- ▼Funds holding -5
- ▼Superinvestors: 1 added, 2 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 153 | 158 | −3.2% |
| In funds' top 10 | 11 | 11 | 0.0% |
| Held by funds | 97.6% | 89.2% | +8.4 pts |
| New / increased | 15 / 70 | 34 / 70 | −18.3% |
| Reduced / sold out | 41 / 20 | 30 / 15 | +35.6% |
| Put/call ratio | 1.27 | 0.00 | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether AVBP is in one of them and how their past AVBP trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered AVBP in an article yet. Here's the latest on the wider market.
About ArriVent BioPharma
ArriVent BioPharma is a clinical stage biopharmaceutical company based in Newtown Square, Pennsylvania. It develops cancer treatments for patients, with its lead candidate, firmonertinib, aimed at non-small cell lung cancer linked to certain EGFR gene mutations. The company is also developing antibody drug conjugates, including ARR 217, for solid tumors. Its candidates are still in clinical trials and have not been approved by the U.S. Food and Drug Administration.
- Headquarters
- Newtown Square, PA


